Assis

Quick links to important sections

Assis

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Assis

Quick Facts About Assis

To provide a rapid overview of the medicine’s identity, here are the core factual properties of the Assis preparation:

Property Description
Active Ingredients Magaldrate and Simethicone
Form Oral suspension or chewable tablets
Pharmacological Class Antacid and Antiflatulent
Common Use Relief of hyperacidity and flatulence
Origin Combination of synthetic inorganic and polymer compounds

What Type of Medicine is Assis? (Identity and Classification)

Assis is a specific brand name for an Over-the-Counter (OTC), fixed-dose combination pharmaceutical preparation designed for oral administration. It is classified as an Antacid and Antiflatulent combination agent, positioned as a fast-acting Gastrointestinal Agent. This dual classification reflects its simultaneous role in addressing two prevalent sources of upper digestive discomfort: excess stomach acid and trapped gas. Assis is utilized for providing relief for functional gastrointestinal upset.

The Dual Composition: Magaldrate and Simethicone

The Assis preparation is defined by its two distinct active ingredients: Magaldrate and Simethicone. Magaldrate is a synthetic inorganic substance, an aluminum-magnesium hydroxide complex, which functions as the acid-neutralizing agent. This compound is noted for its capacity to offer a sustained buffering action. The second component, Simethicone, is an inert, non-systemic synthetic organosilicon polymer used for its physical defoaming action. The specific Assis formulation is often positioned toward adults and adolescents seeking relief from acute indigestion.

General Purpose: Symptomatic Relief from Digestive Distress

The general therapeutic purpose of this combination is to provide effective, local symptomatic relief for acute, non-complicated digestive distress. For instance, Assis is often used by individuals experiencing the burning pain of heartburn or the uncomfortable pressure of bloating. By combining a buffering agent with a physical defoaming agent, the product is intended to target discomfort caused by both hyperacidity and flatulence. This action mitigates the burning sensation associated with acid indigestion and the feeling of pressure and fullness resulting from excess gas accumulation.

What side effects are possible with Assis?

Possible Side Effects and Safety Information

The safety profile for the combination of Magaldrate and Simethicone (Assis) is documented in official regulatory sources, with the majority of known adverse reactions related to the Magaldrate antacid component. The documented side effects are categorized based on their occurrence and the body system affected.


Official Classification of Adverse Reactions

The most frequently documented effects relate to the Gastrointestinal system.

Classification Examples of Reactions
Uncommon Diarrhea, Constipation
Frequency Not Known Hypersensitivity reactions, Abdominal pain, Nausea, Vomiting

Serious Systemic Safety Considerations

The official labeling documents potential for serious, systemic adverse reactions, particularly with prolonged administration or in specific patient populations. These risks are classified under Metabolism and Nutrition Disorders.

  • Electrolyte Imbalance and Toxicity: Systemic accumulation of aluminum (Hyperaluminemia) and magnesium (Hypermagnesemia) is a documented risk, especially in individuals with renal impairment. This accumulation may be associated with neurotoxicity and, in rare instances, encephalopathy.
  • Bone Health: Prolonged use is associated with a risk of Hypophosphatemia (low phosphate levels), which may contribute to conditions like osteomalacia (bone softening).

Safety-Related Constraints

Official regulatory texts include specific cautions regarding use duration and potential interactions. The antacid properties of the medicine can interfere with the absorption of other concurrently administered oral drugs, which is a key safety constraint defined in the product label. Cautious use is officially advised for patients with renal insufficiency due to the increased risk of systemic toxicity.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the manifestations and required emergency actions for an overdose of Assis (an NSAID/antiplatelet agent). Overdose may present with a specific Systemic Manifestation Profile, including early signs like Tinnitus (ringing in the ears), Hyperventilation, Nausea, and Vomiting. Severe presentations can involve Metabolic Acidosis, Hyperthermia, and significant CNS changes such as Drowsiness or confusion.


Immediate Actions and Severe Outcomes

The documentation mandates that individuals must Seek immediate medical attention or contact emergency services for any suspected overdose or the onset of systemic symptoms. This is due to the risk of severe, life-threatening outcomes, including Seizures, Pulmonary edema, Respiratory failure, and Circulatory collapse.


Regulatory Management and Monitoring

No specific antidote is known for this agent's toxic effects; therefore, management focuses on supportive measures and elimination. Official procedures described include gastric decontamination with Activated charcoal and correction of acid-base imbalance via Urinary alkalinization using intravenous sodium bicarbonate. Hospital monitoring is required, including repeated checks of serum salicylate levels and laboratory assessment of blood gases and electrolytes. Regulatory labeling also notes that elderly patients and individuals with existing renal impairment face increased risk of toxicity.

Therapeutic Uses of Assis

Quick Facts

  • Relieves minor aches and pains, such as headache or muscle discomfort.
  • Helps reduce elevated body temperature (fever).
  • May be used to help manage inflammation associated with certain conditions.
  • Prescribed to lower the risk of blood clotting in specific patient populations.

Assis is a medication used to help relieve the symptoms of common conditions that cause minor aches and pains, including muscle pain, joint discomfort, and headache. It also serves to assist in lowering fever in individuals experiencing elevated body temperature.

The medication may be used in the management of inflammation associated with certain conditions, helping to address swelling and related symptoms. Furthermore, under the direction of a healthcare professional, Assis has an important role in the secondary prevention of cardiovascular and cerebrovascular events.

In specific patient populations, this medication is prescribed to reduce the risk of serious conditions such as heart attacks and clot-related strokes. This application is based on its ability to interfere with blood clotting in the vessels, promoting favorable blood flow. For more detailed information on the approved indications and risks, professional medical guidance should be consulted. Assis is intended for use within its indicated therapeutic domains and should only be initiated for cardiovascular protection after a thorough review by a health professional.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Assis?

Eligibility for Assis (Magaldrate/Simethicone) is strictly defined by regulatory authorities based on age, known sensitivities, and existing health conditions.


Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated in patients with a known hypersensitivity or allergy to Magaldrate, Simethicone, or any component. Use is also prohibited in individuals at risk for bowel obstruction or with related severe gastrointestinal conditions. Furthermore, official labeling states that debilitated patients must not use this medicine.


Age-Based and Conditional Eligibility

Assis is intended for adults and adolescents 12 years of age and older. Use in children under 12 years is not established and requires individual determination and dosing by a healthcare provider.


Restricted Use (Use with Caution)

Use requires explicit caution and professional monitoring in populations with severe kidney disorders (renal insufficiency). This restriction is necessary to mitigate the risk of aluminum and magnesium accumulation. Similar caution is advised for individuals with Alzheimer's dementia or those on low-magnesium or sodium-restricted diets. For pregnancy and lactation, the medicine should be used only if clearly needed and under professional guidance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Assis is defined by pharmacokinetic interactions that occur at the level of drug absorption in the gastrointestinal tract. Regulatory documents establish that co-administration of Assis with numerous oral medications can result in a reduced systemic exposure of the co-administered drug. This reduction in bioavailability is caused by the chelation or binding of the interacting medicine by the aluminum and magnesium ions in Magaldrate, as well as by the effect of altered gastric pH.

Official guidance indicates that the severity of this exposure modification is high for agents such as Tetracycline and Quinolone antibiotics, which are subject to prohibited co-administration rules in some labels. For other medicines, including Digoxin, Levothyroxine, and Iron Salts, a mandatory administration separation is required, typically stating that the co-administered drug must be taken two to four hours before or after Assis.

Beyond drug-drug interactions, Magaldrate is documented to bind and decrease the absorption of dietary phosphates. A population-specific constraint exists for individuals with severe renal impairment, where minimal systemic absorption of the ions can lead to an elevated risk of Aluminum and Magnesium accumulation in plasma.

Mechanism of Action

How Assis Works

Mechanism of Gastric pH Buffering

This mechanistic domain covers the action of Magaldrate, which functions by the direct chemical neutralization of free hydrogen ions ( H^+) in the gastric lumen. This reaction immediately elevates the local pH, a subsequent step that not only reduces the corrosive potential of the gastric fluid but also causes the inactivation of the proteolytic enzyme Pepsin. The resulting physiological consequence is the mitigation of acidic exposure to the tissue surface.

Physical Modulation of Gastrointestinal Gas Dynamics

This domain explains the action of Simethicone, which does not interact with biological pathways but operates via a physical defoaming mechanism. Its primary target is the surface tension of gas-liquid interfaces in the GI tract. By reducing this tension, Simethicone facilitates the coalescence of numerous small, stable gas bubbles into fewer, larger, and more unstable pockets. This physical restructuring allows the trapped gas to be more easily cleared from the body, leading to reduced physical pressure and mechanical distension on the GI wall.

Complementary Non-Systemic Action

The combined action stems from the independent yet mechanistically complementary actions of its two components, both of which are non-systemic and confined to the GI lumen. While one component modulates the chemical environment ( pH), the other modulates the physical state (gas pressure). This dual mechanism modulates two distinct physiological states: the chemical environment ( pH) and the physical state (gas pressure).

Dosage and Administration Information

The usage of Assis is defined by an oral administration protocol for the Magaldrate and Simethicone combination. The medicine is available as an oral suspension or as chewable tablets, with the route of intake limited to oral administration.

For the oral suspension, the standard labeled single dose for adults and adolescents 12 years of age and older is typically between 5 mL and 10 mL. Administration is designed for the acute management of symptoms and is scheduled up to three or four times per day. To optimize its use, the dose is generally directed to be consumed after meals and immediately before bedtime.

There are clear constraints regarding the quantity and duration of use. The total volume administered must not exceed a maximum of 80 mL within any 24-hour period. Furthermore, continuous administration at the maximal dose should be limited to a short-term course, not exceeding two weeks. Proper administration of the liquid form requires the suspension bottle to be shaken thoroughly before measuring the exact quantity. The use of this preparation is restricted to individuals 12 years and older, with a procedural note advising caution or dose modification for patients with documented renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Assis

Evidence for Use in Symptomatic Relief of Hyperacidity (Heartburn and Acid Indigestion)

Research has explored the use of the antacid component, Magaldrate, which is found in Assis. This research has involved older Randomized Controlled Trials (RCTs) and observational studies which were applied in research exploring how symptoms change over time. Studies monitored outcomes related to physical discomfort, specifically measuring changes in the acidity of the stomach contents (gastric pH) and how patients reported their symptom intensity for burning or sour taste.

The findings describe patterns observed in the studies where the antacid component's use resulted in measured changes in gastric acidity. Studies report how symptoms evolved in the observed populations during short-term follow-up periods. A limitation is that many of the foundational studies are older, and there is limited information for long-term outcomes or the durability of the symptomatic changes.


Evidence for Use in Symptomatic Relief of Flatulence (Bloating and Gas Discomfort)

The second main area of research is the use of the antiflatulent component, Simethicone, and how studies evaluated bloating and gas discomfort. This component has been more thoroughly studied through modern RCTs and Systematic Reviews. Studies explored outcomes related to physical discomfort, such as the perceived discomfort of abdominal fullness and pressure.

Multiple studies reported findings showing measured changes in gastrointestinal gas patterns. Systematic reviews described patterns of short-term change were observed in patient-reported outcomes describing perceived discomfort related to gas. Despite the relative consistency, a limitation is that follow-up durations were limited, meaning the evidence contributes only to understanding short-term symptom patterns and not long-term management.


Understanding the Gaps: What Research Still Needs to Address

The current evidence highlights what is known—and what is still uncertain—about this combination medicine. The evidence quality varies across studies, particularly for the older antacid research. A key research limitation frame is that long-term effects are not fully established because follow-up durations were limited in most trials. Furthermore, while the components are well-studied individually, comparative evidence is lacking specifically for the fixed-dose combination against other common combination treatments.

Key Studies & References

  1. NIH MedlinePlus guidance (General Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Assis (FAQ)

Q: Is Assis the same as [Name of similar medicine]? How is it different?

A: Official product information describes Assis as a fixed-dose combination containing two distinct active ingredients: Magaldrate and Simethicone. This dual composition is notable because it provides two mechanistically different, non-systemic actions—one to neutralize acid and one to physically break down gas bubbles.

Q: How quickly should I expect to notice anything after starting Assis?

A: According to the official product information, Assis is described as fast-acting and is intended for the acute, on-demand management of symptoms. Because the components act locally in the stomach and intestines, the onset of action is generally rapid.

Q: Is Assis safe for long-term use?

A: Official guidelines establish that continuous administration at the maximal dose is limited to a short-term course, not exceeding two weeks. Prolonged use carries systemic risks, such as the potential for low phosphate levels (Hypophosphatemia).

Q: Are there any food restrictions while taking Assis?

A: Official regulatory documents indicate that the Magaldrate component can bind and decrease the absorption of dietary phosphates. Although the medicine is typically taken after meals to help with acute symptoms, this documented effect is a relevant consideration regarding nutrient absorption.

Q: Will Assis interact with my over-the-counter vitamins or supplements?

A: Yes, the medicine can interact with certain oral medications, including some vitamins and supplements. The official guidance states that many of these products must be taken two to four hours before or after Assis. This separation is part of the mandatory administration guidance to avoid the altered stomach environment from reducing the supplement's absorption.

Q: What happens if I accidentally take too much Assis?

A: If a dose is taken above the maximum limit, it may lead to symptoms such as severe diarrhea, cramps, or stomach problems. This can be due to the accumulation of aluminum and magnesium, and official patient information indicates that professional medical attention may be warranted.

Q: Has Assis been studied in children?

A: Official product information states that Assis is intended for individuals 12 years of age and older. The safety and efficacy of the product have not been established in children under 12 years of age.

Q: What happens if I feel like Assis isn't working for me?

A: Since the product is intended for acute, on-demand symptom management, its official role is limited to short-term relief. If symptoms persist or worsen beyond the maximum recommended two-week treatment period, official documents indicate that professional guidance may be necessary.

Q: Does Assis cause any known issues with the liver or kidneys?

A: Caution is specifically advised for patients with severe kidney disorders (renal insufficiency) due to a documented risk of aluminum and magnesium accumulating in the body. While the primary warning is for the kidneys, official patient guides note that caution may be necessary for individuals with known liver impairment.

Q: What should I do if a side effect of Assis bothers me?

A: Official patient guides recommend that any severe or bothersome side effects be brought to the attention of a healthcare provider. Patients are also encouraged to report all adverse events to the relevant governmental regulatory authority (such as the FDA or MHRA).

Q: Can I take pain relievers like ibuprofen with Assis?

A: Assis can reduce the systemic absorption of other oral medications, including many pain relievers. Due to this potential interaction, a mandatory administration separation is stated in the labeling, typically advising that the pain reliever be taken two to four hours before or after Assis.

Q: Does Assis interact with common cold or flu medicines?

A: Yes, Assis can interact with many oral cold or flu preparations by altering stomach pH or binding to the drug, which reduces its absorption. To avoid this, a mandatory administration separation of two to four hours between the products is described in the labeling.

Q: What kind of monitoring is required while taking Assis?

A: Official labeling indicates that professional monitoring may be warranted for patients with severe kidney disorders (renal insufficiency). This caution is necessary due to the increased risk of systemic accumulation of aluminum and magnesium ions.

Q: Can Assis make my existing medical condition worse?

A: Official product information lists specific contraindications that prohibit use, such as a known risk for bowel obstruction. Furthermore, caution is advised for individuals with existing conditions like renal impairment or Alzheimer's dementia due to the potential for systemic accumulation of the components.

Q: What is Assis used for besides the main condition?

A: Official regulatory labeling defines the use of the combination product strictly for the relief of hyperacidity (heartburn and acid indigestion) and flatulence (bloating and gas discomfort).

Q: What happens if I miss a day of Assis?

A: The medicine is typically used for acute, on-demand relief rather than strict scheduling. If a patient misses a scheduled dose, official patient information states that an extra dose should not be taken, nor should the maximum daily limit be exceeded to try and compensate.

Q: Can I drink alcohol while I am using Assis?

A: Official patient guides state that alcohol consumption may be avoided while using this medicine. Alcohol intake can increase the body’s production of stomach acid, which may counteract the medicine's effect and potentially worsen symptoms of hyperacidity.

Q: Can Assis affect my sleep?

A: While it is uncommon, the systemic absorption of the Magaldrate component, particularly in specific patient groups, has been associated with rare reports of serious central nervous system effects (neurotoxicity). These potential effects could impact alertness or sleep patterns.

Q: Is it normal to feel tired when starting Assis?

A: Official side effect profiles have noted general systemic effects, such as malaise (a general feeling of discomfort). While this may encompass a feeling of tiredness, regulatory documents do not list fatigue as a frequently reported or common side effect.

Q: Why does Assis need to be taken consistently?

A: Regulatory documents establish that this medicine is intended for acute, on-demand symptom management, and is not intended for consistent long-term use. The maximum duration of continuous use is limited to two weeks due to documented safety constraints.

Q: Do I need a special blood test before starting Assis?

A: Official regulatory documents do not state a universal requirement for special blood tests before starting. However, caution and professional monitoring, which may include testing, are advised for patients with renal impairment due to the risk of accumulation.

Q: How long after stopping Assis does it stay in your system?

A: The active ingredients are described as non-systemic, meaning they are minimally absorbed into the bloodstream. Therefore, the primary action of the medicine is localized within the gastrointestinal tract and its effects are not dependent on long-term systemic circulation.

Q: Can I drive or operate machinery while taking Assis?

A: Official patient guides generally state that the use of Assis does not usually affect a person’s ability to drive or operate machinery.

Q: Is Assis habit-forming or addictive?

A: Official patient information explicitly confirms that Assis is not known to be habit-forming or addictive.

Q: Are there any lifestyle changes recommended when taking Assis?

A: Official patient guides may include non-directive information regarding lifestyle adjustments that may help manage symptoms. This may reference the potential benefit of adjustments such as dietary modifications or avoiding certain irritants.

Q: What should I tell my dentist before a procedure if I am taking Assis?

A: Official patient guides advise informing all healthcare providers, including dentists and pharmacists, that the medicine is currently being taken. This is a general safety procedure before any medical procedure.

Q: Does Assis affect laboratory test results?

A: Yes. Regulatory documents state that the Magaldrate component may cause unusual results with certain medical tests. This is specifically noted for imaging procedures like x-rays, CT scans, or MRIs that utilize a radioactive dye.

Q: Why are there different strengths of Assis available?

A: Different strengths and dosage forms, such as the oral suspension and chewable tablets, are made available. This is intended to allow for flexibility in the acute management of varied symptoms and to suit different patient administration preferences.

How should Assis be stored and disposed of?

How to Store and Dispose of Assis?

The storage and disposal of Assis must comply with official regulatory labeling to ensure product stability and safety.

Storage Requirements

Assis must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from moisture and humidity, and must not be frozen. Keep the medicine in its original container and keep the container tightly closed. Store all medication out of the reach and sight of children.


Disposal Instructions

Unused or expired Assis should be taken to a drug take-back program if one is available. If not, the product may be mixed with an unappealing substance, such as coffee grounds, and placed in a sealed bag for disposal in the household trash. Do not flush Assis down the toilet or pour it down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Assis found in:

A-Z Index: